Literature DB >> 3317042

Long-term treatment of alcoholic liver disease with propylthiouracil.

H Orrego1, J E Blake, L M Blendis, K V Compton, Y Israel.   

Abstract

Propylthiouracil has been shown experimentally to protect against alcohol-induced hepatocellular necrosis in hypoxic conditions. An earlier, short-term study of patients with alcoholism and liver disease indicated clinical improvement with propylthiouracil, but the effect on mortality could not be assessed. In the present study, we investigated the effect of propylthiouracil on mortality in patients with alcoholic liver disease in a long-term, double-blind, randomized clinical trial involving 310 compliant patients who received propylthiouracil (n = 157) or placebo (n = 153) for a maximum of two years. There were no differences between the two groups in demographic and clinical characteristics and biopsy-confirmed diagnoses at randomization, or in daily urinary alcohol levels during the study. The cumulative dropout rate over two years was not significantly different (propylthiouracil group, 0.68; placebo group, 0.60). The group receiving propylthiouracil (300 mg per day) had a cumulative mortality rate half that in the group receiving placebo (0.13 vs. 0.25 [P less than 0.05] in the total sample, and 0.25 vs. 0.55 [P less than 0.03] in a subgroup of severely ill patients [propylthiouracil group, n = 56; placebo group, n = 41]). Proportional-hazards stepwise regression analyses indicated that only propylthiouracil treatment, prothrombin time, hemoglobin levels, and mean daily urinary alcohol levels significantly affected mortality. The hazards ratio for the complete group indicated that mortality in the propylthiouracil group was 0.38 (95 percent confidence interval, 0.20 to 0.83) that of the placebo group. Protection by propylthiouracil was not observed in patients with high morning urinary alcohol levels. No clinically important side effects of propylthiouracil were observed at the dose used. We conclude that the administration of propylthiouracil can reduce mortality due to alcoholic liver disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3317042     DOI: 10.1056/NEJM198712033172301

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  24 in total

1.  Alcoholic Liver Disease.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  1999-02

2.  Liver transplantation for alcoholic liver disease: a consideration of reasons for and against.

Authors:  D H Van Thiel; J S Gavaler; R E Tarter; V J Dindzans; R D Gordon; S Iwatsuki; L Makowka; S Todo; A Tzakis; T E Starzl
Journal:  Alcohol Clin Exp Res       Date:  1989-04       Impact factor: 3.455

Review 3.  Interaction of alcohol with other drugs and nutrients. Implication for the therapy of alcoholic liver disease.

Authors:  C S Lieber
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 4.  Current therapy of chronic liver disease.

Authors:  M W Stavinoha; R D Soloway
Journal:  Drugs       Date:  1990-06       Impact factor: 9.546

Review 5.  Propylthiouracil for alcoholic liver disease.

Authors:  Giuseppe Fede; Giacomo Germani; Christian Gluud; Kurinchi Selvan Gurusamy; Andrew K Burroughs
Journal:  Cochrane Database Syst Rev       Date:  2011-06-15

Review 6.  Alcoholic liver disease.

Authors:  K Walsh; G Alexander
Journal:  Postgrad Med J       Date:  2000-05       Impact factor: 2.401

7.  Impaired oxygen utilization. A new mechanism for the hepatotoxicity of ethanol in sub-human primates.

Authors:  C S Lieber; E Baraona; R Hernández-Muñoz; S Kubota; N Sato; S Kawano; T Matsumura; N Inatomi
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

Review 8.  Hepatic disorders. Features and appropriate management.

Authors:  M A Aldersley; J G O'Grady
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

9.  Hemodynamic effects of hypothyroidism induced by methimazole in normal and portal hypertensive rats.

Authors:  R Oren; N Hilzenrat; Y Maaravi; A Yaari; E Sikuler
Journal:  Dig Dis Sci       Date:  1995-09       Impact factor: 3.199

10.  Management of alcoholic hepatitis: Current concepts.

Authors:  Hetal A Karsan; Samir Parekh
Journal:  World J Hepatol       Date:  2012-12-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.